Understanding Relapsed and Refractory Acute Myeloid Leukemia (AML)

Understanding Relapsed and Refractory Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia (AML) is a serious type of blood cancer that originates in the bone marrow and primarily impacts the white blood cells. While treatment can be effective, leading to remission (an absence of cancer cells), sometimes the cancer can return or fail to respond to treatment. This is when we talk about relapsed or refractory AML. Understanding the difference between these two conditions, their potential impact on treatment and outlook, and the available options is crucial for patients and their families. What is Acute Myeloid Leukemia (AML)? AML begins in the bone marrow, the spongy tissue inside bones where blood cells are made. In AML, the bone marrow starts producing abnormal white blood cells, known as blast cells or leukemia cells. These abnormal cells don't mature properly and can't fight infection. As they multiply, they crowd out healthy blood cells, leading to a shortage of red blood cells (causing anemia), white blood cells (increasing infection risk), and platelets (causing bleeding and bruising). Relapsed vs. Refractory AML: The Key Differences When a patient has been treated for AML, and the cancer is still active or returns, it falls into one of two categories: Relapsed AML: This occurs when AML returns after a period of remission. Remission means that tests show no signs of cancer in the body. If AML relapses, it signifies that the cancer has come back after achieving this cancer-free state. Refractory AML: This refers to AML that has not responded to treatment. A doctor might diagnose refractory AML if leukemia cells are still present in significant numbers even after undergoing multiple rounds of treatment, typically two or more chemotherapy induction cycles, without achieving remission. In essence, relapsed AML is a recurrence after a period of success, while refractory AML is a failure to respond to treatment from the outset or after initial attempts. Symptoms of Relapsed or Worsening AML The symptoms of relapsed or refractory AML can be similar to those experienced at the initial diagnosis, but they may worsen or reappear after a period of improvement. It is vital to be aware of these signs and seek medical attention promptly: Easy bleeding and bruising: Due to a low platelet count. Fatigue and weakness: Caused by anemia (low red blood cell count). Frequent infections: Resulting from a low white blood cell count. Fever Shortness of breath Bone pain or tenderness Swollen lymph nodes Loss of appetite and weight loss When to Consult a Doctor: Contact a doctor immediately if you suspect you may have recurring or worsening symptoms of AML. Prompt medical evaluation is crucial for timely diagnosis and management. Diagnosis of Relapsed or Refractory AML Diagnosing relapsed or refractory AML involves a combination of tests to confirm the return or persistence of cancer cells: Complete Blood Count (CBC): A CBC may reveal new leukemia cells and lower levels of normal blood cells. In relapsed AML, a CBC might show these changes indicating the return of cancer. Bone Marrow Biopsy and Aspiration: This is a key diagnostic tool. If you experience relapsed AML, your bone marrow will likely contain at least 5% abnormal white blood cells (blast cells). For refractory AML, the bone marrow will still show a high percentage of blast cells even after treatment. To achieve remission, the bone marrow must have 5% blast cells or less, and CBC levels must be within the normal range. Genetic Testing: For relapsed AML, doctors may perform genetic testing to identify specific mutations that may have developed or were present but not eradicated by initial treatment. This can help guide further targeted therapy. Treatment Options for Relapsed or Refractory AML Treatment for relapsed or refractory AML aims to achieve remission again or manage the disease. The options are often similar and depend on various factors, including the patient's overall health, previous treatments, and the specific genetic mutations present in the leukemia cells. Common Treatment Strategies: Chemotherapy: Re-induction chemotherapy may be used to try and achieve remission again. This might involve different drugs or combinations than those used initially. Targeted Therapy: If specific genetic mutations are identified, targeted therapies can be highly effective. These drugs are designed to attack cancer cells with specific genetic alterations while sparing healthy cells. Examples include: For CD33-positive mutations: Gemtuzumab ozogamicin (Mylotarg) For FLT3 mutations: Gilteritinib (Xospata) or azacitidine (Onureg) with sorafenib (Nexavar) For IDH1 mutations: Ivosidenib (Tibsovo) or olutasidenib (Rezlidhia) For IDH2 mutations: Enasidenib (Idhifa) Stem Cell Transplant (Bone Marrow Transplant): This is a more intensive treatment that can be considered for some patients, especially if they achieve remission with further therapy. It involves replacing the diseased bone marrow with healthy stem cells. Clinical Trials: Participation in clinical trials can offer access to new and experimental treatments that are not yet widely available. The choice of treatment is highly individualized and made in consultation with an oncologist. Outlook and Survival Rates The outlook for individuals with relapsed or refractory AML is generally more challenging than for those who respond well to initial treatment. However, it's crucial to understand that statistics represent broad averages, and individual outcomes can vary significantly. Overall AML Survival Rate: According to data from the National Cancer Institute, the 5-year relative survival rate for AML was 31.9% between 2014 and 2020. This figure encompasses all stages and types of AML, including newly diagnosed cases. Relapsed AML Outlook: For people who experience

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.